CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Mindset Pharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Mindset Pharma Inc
217 Queen Street West, Suite 401
Phone: (647) 938-5266p:647 938-5266 TORONTO, ON  M5V 0R2  Canada Ticker: 9DF9DF
This company was Merged or Acquired on 10/27/2023.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Mindset Pharma Inc. is a Canada-based drug discovery and development company focused on creating optimized and patentable psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. The Company is developing various families of psychedelic compounds, as well as a process to chemically synthesize psilocybin in addition to its own proprietary compounds. The Company, through the McQuade Center, covers multiple drug development programs. The Company has developed 4 families of next-generation psychedelics with differentiated characteristics. The Company's portfolio consists of macrodosing and microdosing. Its macrodosing includes Family 1/MSP-1014, Family 2, and Family 4. The MSP-1014 is a new chemical entity that incorporates a conjugated amplifier into a psilocybin-like structure to create an effective drug. The Company's Family 3 is a long-acting next-generation psychedelic drug positioned for micro-dosing.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/20236/30/2022Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Richard J.Patricio 49 9/11/2020 9/11/2020
Chief Executive Officer James A.Lanthier 46 4/1/2020 4/1/2020
Chief Financial Officer ArvinRamos 43 9/11/2020 9/11/2020
4 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 101,298,924 (As of 5/30/2023)
Stock Exchange: CNQ


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 25, 2024